Physician profile
Harmohinder S Kochar
NPI 1720086002
$10,396.85
in general payments reported to CMS, 2019-2025
30 companies · $3,642 in 2025
The $3,642 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $137 · 2021: $321 · 2022: $1,351 · 2023: $1,309 · 2024: $2,999 · 2025: $3,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,850 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,849.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $1,663.96 | 2019-2025 | Smartvest |
| Philips North America LLC | $1,584.89 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Home Pi Undivided |
| Glaxosmithkline, LLC. | $1,316.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,044.57 | 2022-2025 | Tezspire, Breztri, Airsupra |
| Genzyme Corporation | $528.57 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.78 | 2021-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $475.93 | 2021-2025 | Dupixent |
| Verona Pharma, INC. | $444.15 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $431.05 | 2022-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $282.54 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Viatris Specialty LLC | $216.98 | 2025 | Yupelri |
| Pulmonx Corporation | $213.73 | 2019-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Harmony Biosciences LLC | $202.34 | 2022-2025 | Wakix |
| Inspire Medical Systems, INC. | $178.26 | 2023-2025 | Inspire |
| Amgen INC. | $168.97 | 2024-2025 | Tezspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $159.67 | 2019 | |
| Insmed, INC. | $149.93 | 2023-2025 | Arikayce |
| Shionogi INC | $144.31 | 2023-2025 | Fetroja |
| Sunovion Pharmaceuticals INC. | $142.31 | 2019-2020 | |
| Allergan, INC. | $124.15 | 2019 | |
| Inogen, INC. | $88.32 | 2022 | |
| Tactile Systems Technology INC | $84.08 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Lilly USA, LLC | $49.98 | 2025 | Zepbound, Mounjaro |
| Resmed Corp | $49.96 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $34.56 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $34.08 | 2025 | Lumryz |
| Zoll Respicardia, INC. | $32.30 | 2023-2024 | Remede System |
| Johnson & Johnson Health Care Systems INC. | $30.21 | 2024 | Uptravi, Opsumit |
| Phadia US INC. | $22.96 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $19.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmohinder Kochar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.